Weill Cornell Medical College Sandra & Edward Meyer Cancer Center | Strategic Alliance Partners

March 11, 2024

A panel medical oncologists provide an overview of circulating tumor DNA and its role in MRD (minimal residual disease) testing in the treatment of patients with colorectal cancer.

February 28, 2024

Manish A. Shah, MD, discusses how pembrolizumab with chemotherapy impacts immune responses in advanced esophageal cancer according to PD-L1 status.

February 26, 2024

Manish A. Shah, MD, discusses 5-year outcomes from phase 3 KEYNOTE-590 study of first-line pembrolizumab plus chemotherapy for advanced esophageal cancer.

February 24, 2024

In a retrospective analysis, Orca-T improved survival rates vs PTCy in patients with hematologic malignancies receiving myeloablative conditioning.

February 20, 2024

A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.

February 13, 2024

A panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.

February 13, 2024

Experts on mantle cell lymphoma discuss third-line treatment options available for patients.

February 06, 2024

Experts on mantle cell lymphoma discuss second-line treatment options available for patients.

February 06, 2024

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.

January 30, 2024

Experts on mantle cell lymphoma discuss first-line treatment options available for patients.

January 30, 2024

Laurie Sehn, MD, and Bijal Shah, MD, discuss remaining unmet needs for patients with relapsed/refractory FL.

January 23, 2024

Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.

January 23, 2024

Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.

January 20, 2024

Neoadjuvant botensilimab/balstilimab led to robust responses in both patients with resectable mismatch repair–proficient and –deficient colorectal cancer.

January 16, 2024

A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.

January 16, 2024

Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.

January 10, 2024

Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.

January 10, 2024

Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.

January 02, 2024

Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.

January 02, 2024

Experts on follicular lymphoma discuss second-line treatment options available for patients.